Fragmental releases of efficacy data for the COVID-19 vaccine developed by China's Sinovac could undermine confidence in the shot, experts warned, as several countries prepare for mass inoculations with the vaccine. Brazil has also delayed release of its efficacy data on the vaccine three times, as Sinovac seeks to consolidate data from global trials that include Indonesia, Turkey and Chile. With efficacy data in Turkey based on just 1,322 subjects and small infection cases, experts say more data from a larger number of participants would be needed to seek regulatory approval. "It's difficult to determine how well (the) Sinovac vaccine works based solely on 29 coronavirus cases," Kim said. "It would be good to have more volunteers and more infections, which would boost the robustness of the efficacy data."

Source: Mint December 28, 2020 10:41 UTC